Are you in Barcelona for #ESMO2024 in September? Meet SOPHiA GENETICS to find the right patients, for the right trials with SOPHiA DDM™ Trial Match! 🎯 Explore real-world data from our vast network to enhance your clinical trials on a global scale. Improve site selection, identify the right biomarkers and patient populations, and shorten enrolment timelines, with on-demand access to the SOPHiA DDM™ Platform. Get more out of ESMO 2024 and book a meeting with us to learn how SOPHiA DDM™ Trial Match can help you accelerate clinical trial enrolment: 🔗 https://loom.ly/3pG0cZA #PrecisionOncology #PrecisionMedicine #AIforHealthcare #ClinicalTrials #Genomics #DataDrivenMedicine
SOPHiA GENETICS
Biotechnologieforschung
Democratizing Data-Driven Medicine, Together!
Info
SOPHiA GENETICS is the creator of SOPHiA DDM™, a cloud-based platform capable of analyzing data and generating insights from complex multimodal data sets and different modalities. The SOPHiA DDM™ Platform enables healthcare institutions to get quick, robust insights from their data. We apply our technology to areas such as cancer and inherited disorders, where combining genomic and phenotypic information is vital to support research and drug development efforts. SOPHiA GENETICS' data-sharing methodology also helps researchers and healthcare professionals work together as a community by sharing and leveraging patterns identified via artificial intelligence and machine learning. Our universal platform is designed to improve as we analyze more data over time. The SOPHiA DDM™ Platform is one of the largest technology-agnostic networks of connected healthcare institutions worldwide and is currently used by more than 750 hospital, laboratory, and biopharma institutions globally. ___________ SOPHiA GENETICS Community Guidelines We value the insights and perspectives of all our members. To ensure a constructive environment, we kindly ask everyone to adhere to the following guidelines: - Respectful interactions: treat everyone with respect and courtesy. - Constructive sharing: contribute comments and ideas that are relevant and add value to the conversation. - Stay on-topic: ensure your comments are relevant to the post or discussion. - Avoid inappropriate content: refrain from posting content that is unethical, hateful, offensive, speculations about our stock prices or financial discussions that are not in the scope of the social media platform. - No spam or solicitations: for business inquiries or other topics, kindly use the 'Contact Us' section on our official website. - Moderation rights: we reserve the right to remove comments that do not align with our guidelines, principles and values. By participating in our community, you agree to these guidelines.
- Website
-
http://www.sophiagenetics.com/
Externer Link zu SOPHiA GENETICS
- Branche
- Biotechnologieforschung
- Größe
- 201–500 Beschäftigte
- Hauptsitz
- Rolle
- Art
- Privatunternehmen
- Gegründet
- 2011
- Spezialgebiete
- Bioinformatics, Algorithms, genomics, big data, clinical, artificial intelligence, AI, Machine Learning, Deep Learning, Oncology, Cancer, ctDNA, Liquid Biopsy, Data-Driven Medicine, Precision Medicine und AI in Healthcare
Orte
-
Primär
La Pièce 12
Rolle, 1180, CH
-
185 Dartmouth St
Floor 5
Boston, Massachusetts 02116, US
-
Technopole Izarbel 158 allée Fauste d’Elhuyar
Bidart, 64210, FR
Beschäftigte von SOPHiA GENETICS
Updates
-
Our social media newsletter is here, showcasing how innovations are heating up at SOPHiA GENETICS! 🔥 From exploring the critical role of MRD in AML to diving deep into the IVDR transition and learning about Jurgi Camblong's, our CEO and Co-founder, opinion on #LiquidBiopsy, this past month has been packed with impactful updates. Ready to catch up on everything that’s happened? Don’t miss our latest LinkedIn newsletter, where we share the highlights and look ahead to two of September’s major events. #Innovation #Healthcare #PrecisionMedicine #DataDrivenMedicine #Newsletter
-
🎓 EPFL students, are you excited about the potential of having an impact on the future of healthcare? Join us at SOPHiA GENETICS for an Open Doors event on September 12th, in collaboration with the BSNL. We are proud to welcome the talents of tomorrow! Discover how we pioneer innovation to impact people's lives from our inspiring experts: Dinis Luís Barros, Tommaso Coletta, Pascal-Antoine Christin, Balazs Laurenczy, Adrian Janiszewski, and Julie Romain. Also, enjoy pizza and drinks while networking and exploring exciting career paths. Are you an EPFL student specializing in Data Science? Apply to join our event by submitting a brief motivation letter to info@bsnl.ch by Friday, August 31st. The BSNL will notify you regarding your application status shortly thereafter. Limited spots, so don’t miss out! BSNL BioScience Network Lausanne #EPFL #OpenDoors #Healthcare #StudentLife #Networking #Career
-
We’re honored by today’s #media coverage featuring Jurgi Camblong, our CEO and co-founder! It highlights the innovative work we're doing at SOPHiA GENETICS to harness AI for advancing cancer diagnostics in public hospitals and beyond. We're committed to driving innovation and creating jobs in the region through our offices in Bidart and Pessac, and extending our impact around the world. Our progress is fueled by our strong #community of customers and partners, who are united in our mission to build the future of healthcare, both locally and globally. Dive into this insightful interview in Basque to learn more: https://lnkd.in/dXJWEUBT Thank you to Berria.eus for the great feature. Eraiki dezagun etorkizuna elkarrekin! #AIforGood #AIforHealthcare #Healthcare #DataDrivenMedicine #BasqueCountry #Press
-
📣 SOPHiA DDM™ Dx Homologous Recombination Deficiency (HRD) Solution is recognized as a validated #HRD detection method in the latest ESMO recommendations for next-generation sequencing (NGS). Considering the potential benefit of PARPi, ESMO recommends carrying out BRCA1/2 and HRD testing using a validated assay in patients with advanced ovarian cancer. 💡 SOPHiA DDM™ Dx HRD Solution is a CE-IVD marked, decentralized application that leverages low-pass whole genome sequencing data to accurately detect HRD status in ovarian cancer and inform treatment decision-making. Read the full ESMO recommendations here: https://loom.ly/CSz9Vcs Learn more about our deep learning-based approach to HRD assessment here: https://loom.ly/vF3tNOY #NGS #PrecisionMedicine #OvarianCancer
-
In his latest article at The Pathologist, Jurgi Camblong, our Co-Founder and CEO, discusses the marvelous potential for liquid biopsy to revolutionize cancer care. From enabling data-driven testing of tumors that would otherwise be difficult to biopsy, to expediting clinical decisions, to streamlining patient monitoring, liquid biopsy can transform precision oncology. Read more: https://lnkd.in/dA75Eb6R #LiquidBiopsy #NGS #PrecisionOncology #PrecisionMedicine
-
📣 #ESMO 2024 Topic Takeover No. 3 🩸 Decentralizing MSK-ACCESS® powered with SOPHiA DDM™ MSK-ACCESS® powered with SOPHiA DDM™, a decentralized version of the rigorously validated cell-free DNA (cfDNA) assay developed and regularly used in clinical routine by Memorial Sloan Kettering Cancer-Center (MSK). SOPHiA GENETICS is working on decentralizing this comprehensive liquid biopsy assay, that includes 146 key cancer-associated genes, to increase access to liquid biopsy testing all over the world. Get more out of ESMO 2024 and book a meeting with us to learn about SOPHiA GENETICS Liquid Biopsy solutions: https://lnkd.in/dpkACUUr #ESMO2024 #PrecisionOncology #PrecisionMedicine #AIforHealthcare #LiquidBiopsy #DataDrivenMedicine
-
🚀 Customer interview: discover the critical role of #MRD in AML! The evolving clinical landscape increasingly recognizes the critical role of measurable residual disease (MRD) in acute myeloid leukemia (AML). Listen to our customers sharing insights: ↳ Yuwen Li, PhD, Assistant Professor, Director of Molecular Genetics Laboratory, Tulane University ↳ Otto Zach, PhD, Head of Laboratory, Laboratory for Molecular Diagnostics, Ordensklinikum Linz Why MRD Matters: • Relapse Prediction: Early detection for timely intervention. • Prognostic Insights: Tailored treatment plans for better outcomes. • Disease Monitoring: Continuous assessment for effective management. • Clinical Trials: Enhancing the accuracy and relevance of study endpoints. Discover the benefits of longitudinal monitoring and hear expert perspectives on NGS-based testing for MRD assessment. 🎥 Watch the complete interview to learn about the latest recommendations: https://loom.ly/h6lAu4g #DataDrivenMedicine #CustomerCentric #PrecisionMedicine #CancerResearch #NGS #HealthcareInnovation
-
SOPHiA GENETICS reported second quarter 2024 financial results today, featuring consistent revenue growth with reported revenue of $15.8 million. In addition, there was strong new business momentum in the second quarter, with 20 new core genomic customers landed in the quarter and strong traction in the NORAM market, with 40% year-over-year analysis volume growth. The company continued to improve the bottom line with a 25% improvement to operating loss and a 32% improvement in adjusted operating loss. "We delivered another quarter of strong forward-looking indicators and continued bottom-line improvements in Q2,” said Jurgi Camblong, PhD., Chief Executive Officer and Co-founder. "Looking ahead, we remain confident in our long-term growth and in the growth prospects of our end markets. Exciting catalysts such as the continued success of MSK-ACCESS® powered with SOPHiA DDM™, a suite of new applications launching this year, and refreshed momentum in our BioPharma business offer meaningful upside and give us conviction in a medium-term growth recovery.” 🔗 Read more in our full earnings press release: https://lnkd.in/dbw2N7CT #Earnings #PressRelease #DataDrivenMedicine
-
📣NEW WEBINAR ALERT! Join us for the second episode of our webinar series "Decoding Complexity – Overcoming Real-World Challenges in Variant Analysis", where we delve deeper into the complexities of variant analysis! 💡In this episode: Advanced Techniques for Detecting Low Allele Frequency Variants! In this session, we are privileged to host two experts from SOPHiA GENETICS: Lin Song, Director of Algorithm Development, and Yvan Wenger, Manager of Bioinformatic Product Development. The focus of this webinar will be our SOPHiA DDM™ algorithm PEPPER™, which is our proprietary SNV and Indel detection technology. 🧬 PEPPER™ utilizes a range of techniques to distinguish true signals from noise, ensuring precise variant calling. ➡️ Lin will highlight the strategies PEPPER™ employs to detect low allele frequency variants, by ensuring accurate distinction from library preparation and sequencing noise. This capability is crucial, especially in liquid biopsy. Yvan will present a use case demonstrating how PEPPER™ addresses the technical challenges of liquid biopsy, focusing on our application MSK-ACCESS powered with SOPHiA DDM™. Don’t miss this chance to gain insights into our innovative methodologies for distinguishing signal from noise for low allele frequency variants. 🎬 Watch now! https://loom.ly/ebW4t8c
Ähnliche Seiten
Finanzierung
Letzte Runde
Fremdkapital nach Börsengang15.000.000,00 $
Investor:innen
Perceptive Advisors